Tage when chemotherapy initially received I-III IV Finest response on prior immunotherapy Partial response Steady disease Progression Unknown Time on prior immunotherapy Median, months (range) ,6 6 to , 12 12 Time amongst prior immunotherapy and random assignment Median, months (range) ,six 6 to , 12 12 two.six (0.7-21.4) 43 four 12 2.4 (0.7-16.three) 62 7 five two.5 (0.7-21.4) 105 13 18 eight.3 (two.8-56.eight) 18 23 18 7.eight (0-43.7) 22 36 16 eight.0 (0-56.eight) 41 59 36 17 30 12 31 34 eight 1 48 66 21 1 34 25 17 57 52 84 NA 50 50 13 27 18 1 66 0 5 three 82 27 23 4 1 three 26 32 47 23 1 75 55 1 1 four 36 23 32 42 69 67 Chemotherapy Followed by Immunotherapy (n five 59) Mixture Immunotherapy and Chemotherapy (n 5 74) Totala (N five 136)Abbreviations: NA, not available; NOS, not otherwise specified; RP, ramucirumab plus pembrolizumab; SOC, regular of care. a Total to include all patients, but three sufferers who received immunotherapy followed by chemotherapy not described separately.seem to differ by PD-L1 or TMB subgroups (Fig 3A). OS advantages were constant across the majority of prespecified subgroups examined. Appendix Table A(on the web only) describes genomic alterations detected with next-generation sequencing as part of Lung-MAP screening.2300 2022 by American Society of Clinical OncologyVolume 40, IssueRamucirumab and Pembrolizumab in NSCLC Just after Prior ImmunotherapyTABLE 3. Grade three Treatment-Related AEs five and All Grade 4 and 5 Treatment-Related AEsSOC (n five 60) Grade AE Acidosis Acute kidney injury ALT increased Anemia AST enhanced Bronchopulmonary hemorrhage Cardiac arrest Colonic perforation Death NOS Dehydration Dyspnea Fatigue Febrile neutropenia GI disorders–others, specify Hypertension Hypotension Hypoxia Lung infection Lymphocyte count decreased Mucositis oral Multiorgan failure Nausea Neutrophil count decreased Pericardial effusion Platelet count decreased Pneumonitis Pneumothorax Respiratory failure Sepsis Wheezing WBC decreased Maximum grade all hematologic AEs Maximum grade all nonhematologic AEs Maximum grade any AE 13 (22) 13 (22) 13 (22) 17 (28) 4 (7) 15 (25) 4 (7) 15 (25) 4 (7) 4 (7) two (3) 1 (two) two (three) two (3) 2 (three) 1 (1) 1 (1) five (7) 21 (30) 22 (32) 1 (1) 4 (six) 4 (six) three (four) 3 (4) three (5) 1 (2) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) three (5) 6 (ten) 14 (23) 1 (2) 2 (three) two (3) 1 (2) 4 (7) 10 (17) 3 (five) 1 (two) 1 (two) 1 (2) 1 (1) 2 (3) 1 (1) 1 (two) 1 (two) 1 (1) 3 (4) 3 (four) 1 (1) 1 (1) 3 (five) two (3) four (7) 2 (three) 1 (two) 1 (two) 9 (13) 1 (2) two (3) 4 (6) 1 (1) 1 (1) 1 (2) 1 (two ) 1 (1) 1 (two) 4 (7) 1 (2) 1 (two) two (three) 1 (1) 1 (1) 3 four 1 (two) 1 (two) 1 (two) 4 (6) 1 (1) 5 3 RP (n five 69) Grade 4NOTE.FGF-2 Protein custom synthesis Information are represented as No.Semaphorin-3F/SEMA3F Protein Synonyms ( ).PMID:23910527 Abbreviations: AE, adverse event; NOS, not otherwise specified; RP, ramucirumab plus pembrolizumab; SOC, normal of care.PFS At the time of evaluation, 119 PFS events had been reported. PFS was not drastically longer with RP, with the one-sided P worth from the regular log-rank test equal to .25 and .14 from the weighted log-rank test (HR: 0.86 [80 CI, 0.66 to 1.14]; Fig 2B). The medianPFS (80 CI) was four.5 (four.two to six.1) months for RP and five.2 (four.2 to five.7) months inside the SOC arm. Subgroup analyses had been constant with those for OS (Fig 3B). Response and Illness Manage On RP, there have been 12 confirmed partial responses and 3 unconfirmed partial responses for an objectiveJournal of Clinical OncologyReckamp et alTABLE 4. Grade three Treatment-Related AEs five and All Grade four and 5 Treatment-Related AEs on Common of Care by Kind of TreatmentDocetaxel Plus Ramucirumab (n five 44) Grade A.